ArticleFrontiers in oncology2026
The value of multimodal ultrasound imaging in differentiating HER2-positive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated vascular differences between human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative breast cancers using multimodal ultrasound and evaluated their diagnostic utility. Methods: Breast masses were examined with conventional ultrasound (CUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), and super-resolution ultrasound (SRUS). Quantitative and qualitative parameters were extracted. Binary logistic regression was used to identify independent predictors of HER2-positive breast cancer. The diagnostic performance was evaluated by receiver operating characteristic (ROC) curve. Results: 72 breast masses were divided into HER2-positive (n = 23) and HER2-negative (n = 49) groups according to immunohistochemical results. Univariate analysis showed that 12 parameters of four ultrasound modalities were significantly different between the groups (p < 0.05), whereas multivariate analysis showed differences in 8 parameters. Maximum diameter of the lump, microcalcification, peak intensity and max flow velocity of HER2-positive group were significantly greater than HER2-negative group ( Conclusions: Multimodal ultrasound parameters from CUS, CEUS, and SRUS can predict HER2-positive breast cancer, and their combination provides superior diagnostic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.